Background: Several studies used the ratio of progression-free survival (PFS) on genotype-matched treatment to PFS on genotype-unmatched treatment to assess the efficacy of therapy guided by patients' tumor molecular profiling. We evaluated the PFS ratio from patients who cross-over in the SHIVA trial.
Introduction
Conflicting results exist on whether anticancer agents given based on patients' tumor molecular profiling in a histology-agnostic way improve patients' outcome. We recently reported the results of the randomized phase II SHIVA trial that compared the efficacy of molecularly targeted agents (MTAs) given outside their indications based on tumor molecular profiling versus treatment at physician's choice (TPC) in patients with any kind of cancer who failed standard-of-care therapy [1] . No statistical difference in terms of progression-free survival (PFS) was detected between the two arms, while several non-randomized studies have reported a benefit of genotype-matched therapy as compared with genotype-unmatched therapy [2] [3] [4] [5] .
Some of these studies used the ratio of PFS on genotypematched treatment to PFS on genotype-unmatched treatment to assess the efficacy of therapy guided by patients' tumor molecular profiling [2] [3] [4] . Ongoing clinical trials such as the WINTHER trial also use the PFS ratio as a primary end point to evaluate the efficacy of genotype-matched therapy. Using the PFS ratio as an end point is appealing when mixing patients with various histologies and prognoses, each patient being used as his/her own control, therefore overcoming patient heterogeneity. The first and pilot study to assess the value of a histology-agnostic treatment approach used the PFS ratio as a primary end point, and reported a 27% proportion of patients with a PFS ratio exceeding 1.3 [2] . Tsimberidou and colleagues retrospectively reported a statistically longer PFS on genotype-matched therapy then on previous genotype-unmatched therapy in phase I cancer patients [3, 4] . One criticism of these studies has been the retrospective evaluation of PFS on prior genotype-unmatched therapy [6] .
We aimed to evaluate the PFS ratio from patients who crossover in the SHIVA trial, with both PFS having been assessed during the clinical trial according to RECIST [7] .
Patients and methods

Study design
SHIVA was an open-label, French, academic, multicentric, randomized, phase II trial of MTAs based on tumor molecular profiling versus TPC in refractory cancer patients. The study was promoted by the Institut Curie in Paris, and conducted at eight sites in France [1] . Adult patients with any kind of recurrent and/or metastatic solid tumor who failed standard of care therapy were enrolled from October 2012 to July 2014 [1] .
The molecular profile of patients' tumors was established based on samples from a mandatory biopsy/resection of a metastasis. Molecular analyses included the evaluation of mutations using targeted next generation sequencing (NGS), gene copy number alterations using Cytoscan HD, and expression of estrogen, progesterone and androgen receptors by immunohistochemistry [1] .
If one or several molecular alterations matching the MTAs available in the frame of the trial were identified, patients were randomized with a 1:1 ratio. Randomization was stratified according to three altered signaling pathways (the hormone receptors pathway, the PI3K/AKT/mTOR pathway, and the RAF/MEK pathway), and patients' prognosis based on the Royal Marsden Hospital (RMH) score [8] . A cross-over was proposed at disease progression for patients in both treatment arms (Figure 1) .
The study was approved by the Ile-de-France ethics committee. All patients provided written informed consent. The trial was conducted according the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Conference on Harmonization, and relevant French and European laws and directives. This trial is registered with ClinicalTrials.gov, number NCT01771458.
Treatments
MTAs used in the experimental arm were only drugs that were approved for clinical use in France, but outside their indications. MTAs among the 11 available in the frame of the trial were selected following a pre-defined treatment algorithm [1] . Treatments in both arms were given according to the approved product information and standard practice protocols at each institution and were continued until evidence of disease progression.
Statistical analysis
The primary end point of the study was PFS defined as the time from randomization to death from any cause or progression according to RECIST 1.1 [7] . Secondary end points included the safety and overall response rate (ORR), as well as PFS in patients who crossed-over. Tumor assessments were done before starting study treatment, and every eight weeks thereafter. Cross-over data are reported here.
For the cross-over analyses, the PFS on MTA (PFS MTA ) and on TPC (PFS TPC ) in both arms after randomization (PFS1) and after the crossover (PFS2) were determined ( Figure 1 ). PFS1 was defined as the time from randomization to the first documentation of disease progression. PFS2 was defined as the time from cross-over selection date to the second documentation of disease progression or death in a same patient. PFS2 was censored if the patient was alive without disease progression. In this latter case, PFS2 was defined as the time from cross-over selection date to the study exit date. The ratio of PFS MTA to PFS TPC was estimated in the group of randomized patients who crossed-over from TPC to MTA or MTA to TPC arms. This approach allowed considering each patient as his/her own control. Patients who crossed-over without the documentation of disease progression were excluded from the PFS ratio analyses. When PFS2 was censored, the PFS ratio was estimated using the KaplanMeier method [9] .
The PFS estimates are presented as Kaplan-Meier curves. No imputation of missing data or adjustment for multiplicity of comparisons of clinical data was carried out. All tests were bilateral at the 5% level. All analyses were carried out by the sponsor using data obtained as of the cutoff date of 12 April 2016, with the R software (version 2.13).
Results
Patient characteristics
Enrollment started on 4th October 2012 and stopped on 11th July 2014 after the inclusion of 741 patients. At the cutoff date, a Figure 1 . Study design. R, randomization; MTA, molecularly targeted agent; TPC, treatment at physician's choice; PFS, progression-free survival.
total of 197 patients (27%) had been randomized, and 95 patients had crossed-over (70 patients from TPC arm to the MTA arm, and 25 patients from the MTA arm to the TPC arm) ( Figure 2 ). Baseline characteristics of patients who crossed-over and those who did not are presented in Table 1 . Patients who did cross-over had a better RMH score then patients who did not. Median overall survival was 10.9 months [95% confidence interval (CI): 9.2-16.4] for patients who crossed-over, as compared with 3.6 months [95% CI: 3.4-5.6] for patients who did not. 
Treatments' efficacy
PFS ratio estimates
The PFS MTA /PFS TPC ratio exceeded 1.3 in 37% [95% CI: 26%-52%] of patients who crossed-over from the TPC arm to the MTA arm (supplementary Table S1 , available at Annals of Oncology online), including 23% of patients with a ratio exceeding two. The ratio was comprised between 1 and 1.3, 0.7, and 1.0, and was below 0.7 in 10%, 29%, and 24% of patients, respectively. The PFS MTA /PFS TPC ratio exceeded 1.3 in 61% [95% CI: 44%-85%] of patients who crossed-over from the MTA arm to the TPC arm (supplementary Table S1 , available at Annals of Oncology online), including 31% of patients with a ratio exceeding two. The ratio was comprised between 1 and 1.3, 0.7 and 1.0, and was below 0.7 in 13%, 13%, and 12% of patients, respectively. The proportion of patients with a PFS ratio exceeding 1.3 was higher in the subgroup of patients treated with MTAs targeting the RAF/MEK pathway then in patients treated with hormone therapy or everolimus (supplementary Table S1 , available at Annals of Oncology online).
The PFS MTA and PFS TPC of the 35 patients with a PFS ratio exceeding 1.3 are presented in Figure 4 . The treatments received by the latter patients as well as their druggable molecular alterations are reported in Table 2 . Most frequently targeted molecular alterations in these patients were PI3KCA mutations and PTEN loss in the PI3K/AKT/mTOR pathway in patients with various tumor types, and androgen receptor overexpression, mainly in patients with gynecological malignancies. Notably, two patients with adenoid cystic carcinoma harboring a PDGFRA amplification treated with sorafenib had a PFS ratio exceeding 1.3.
Discussion
Our study evaluated the ratio of the PFS on MTAs based on tumor molecular profiling to the PFS on TPC with both PFS being assessed during the trial. The ratio exceeded 1.3 in 37% of patients who crossed-over from the TPC arm to the MTA arm, and 61% of patients who crossed-over from the MTA arm to the TPC arm. Original article
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While these proportions are quite high, we acknowledge that only few patients had a prolonged PFS on either treatment, as illustrated with median PFS ranging from 2.0 to 2.8 months.
These ratios compare favorably to the 27% ratio reported in the von Hoff's study [2] . The differences observed with the results of the von Hoff's study might relate to the different treatment algorithms or the range of molecular alterations that were detected in both studies. In the SHIVA trial, treatments in the experimental arm were only MTAs given based on DNA mutations or gene copy number alterations and hormone receptor overexpression [10] . In the von Hoff's study, a variety of drugs were given, sometimes in combination, including not only MTAs and hormone therapy, but also cytotoxic agents and drugs given outside the field of oncology such as metformin, based on RNA molecular alterations using FISH and microarray, and on protein overexpression [2] .
The substantial difference between the proportions of patients with a ratio exceeding 1.3 reported in the group of patients who crossed-over from the TPC arm to the MTA arm (37%) and the group of patients who crossed-over from the MTA arm to the TPC arm (61%) might be explained by two factors: (i) the small number of patients (25) in the latter group, reflected by the large confidence interval, and (ii) the tumor growth kinetics that should be exponential if one makes the hypothesis that all tumor cells of a cancer divide at the same pace [11] . If this hypothesis holds true, tumor growth kinetics, and therefore PFS, should shorten along the disease evolution, with a PFS2 being shorter than PFS1. Although this hypothesis is debated, our results support it, since the proportion of patients with a PFS MTA /PFS TPC ratio exceeding 1.3 was higher when patients who received the MTA first. Considering this, it would mean that the combined proportion of patients with a ratio exceeding 1.3 in the SHIVA trial lies somewhere between 37% and 61%.
More patients did cross-over from the TPC arm to the MTA arm than vis-versa. This observation is likely due to the fact that (i) patient and investigator motivation to stay in the study decreased once patients were treated in the experimental arm, and (ii) some patients might have subsequently been eligible for other clinical trials at disease progression following treatment in the experimental arm, potentially on the basis of a molecular alteration identified in the SHIVA trial. This has led to an imbalance between the two arms in the cross-over analysis. It was therefore not possible to estimate the true treatment effect adjusted on the treatment sequence effect by taking into account the interaction with the treatment sequence.
Using the PFS ratio as an end point is associated with several pitfalls. First, it relies on the assumption that tumor growth kinetics is linear over time as mentioned earlier. Second, results only apply to patients who indeed did cross-over. The prognosis of patients who did not cross-over in the SHIVA trial was far worse than the ones who did, as reflected by a shorter overall survival and a higher proportion of patients with a poor RMH score. The results can therefore not be extrapolated to the whole population of the randomized patients in the SHIVA trial.
In our study, PFS1 was defined as the time from randomization to the first documentation of disease progression. In fact, PFS1 was a time-to-progression (TTP), since death was not a possible event during PFS1 in order to be included in the cross-over analysis. On the contrary, PFS2 was a real PFS, since death would account as an event. From a statistical point of view, it might have been more relevant to evaluate the TTP ratio instead of the PFS ratio, so that similar measures are taken into account in the estimate of the ratio. On the other hand, using TTP2 instead of PFS2 would have meant to consider death as a censure, which might not be relevant from a clinical point of view. Using the TTP ratio instead of the PFS ratio would therefore under-estimate the proportion with PFS ratio exceeding 1.3 for patients receiving TPC first, and over-estimate this proportion in patients receiving the MTA first. The proportion of patients with a TTP ratio exceeding 1.3 in the group of patients who crossed-over from the TPC arm to the MTA arm was 41% (instead of 37% for the PFS ratio) (supplementary Table S1 , available at Annals of Oncology online). The proportion of patients with a TTP ratio exceeding 1.3 in the group of patients who crossed-over from the MTA arm to the TPC arm was 61% (similar to the PFS ratio) (supplementary Table S2 , available at Annals of Oncology online). Our study has several limitations. First, the cross-over analysis is a post hoc analysis of data from a randomized phase II trial for which the analysis of the primary endpoint showed no difference between the treatment arms. Second, this analysis only contains a subset of patients from the parent trial and that there is a much greater portion of patients that were initially randomized to the TPC arm. Third, one cannot fully exclude that PFS on MTA might have been over-estimated since MTAs might be perceived to be the more rationale therapy by the investigator and further therapeutic options limited.
While the result of the SHIVA trial was negative for its primary end point (i.e. PFS), the cross-over analysis enabled to identify a substantial proportion of patients who seem to have benefited from the treatment algorithm evaluated in the SHIVA trial. Taking each patient as his/her own control by using the PFS ratio as a primary end point might be a relevant option in algorithm-testing precision medicine trials mixing various histologies and treatments, in order to control for patient heterogeneity [12] .
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